Teratologic Evaluation of Scopolamine Hydrobromide (CAS No. 114-49-8) Administered to CD-1 Mice on Gestational Days 6 through 15

摘要

Scopolamine hydrobromide (SCOP), a naturally occurring anticholinergic drug, was evaluated for toxic and teratogenic effects in timed-pregnant CD-1 mice. Animals were exposed to SCOP in water, by gavage on gestational days (gd) 6 through 15 and sacrificed on gd 17. Prior to initiation of the teratology study, a preliminary study was conducted in order to establish appropriate doses for use in the teratology study. Based on the results of the preliminary study, doses of 0, 10, 100, 450, or 900 mg/kg/day SCOP were administered in the teratology study. In conclusion, SCOP administered to pregnant CD-1 mice during the period of major organogenesis at doses up to 900 mg/kg/day had no adverse effect on prenatal viability, produced no evidence of teratogenesis, and caused only a marginal reduction in fetal body weight at doses of 450 and 900 mg/kg/day, that also caused marginal maternal toxicity.